Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review

Li,Jingbo; Chen,Shuda; Hu,Yinghong; Cai,Jing

doi:10.3892/ol.2016.4204

March-2016 Volume 11 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2016 Volume 11 Issue 3

Full Size Image

Case Report

Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review

Authors:
- Jingbo Li
- Shuda Chen
- Yinghong Hu
- Jing Cai
View Affiliations / Copyright

Affiliations: Intensive Care Unit, The Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Pages: 2255-2260
|
Published online on: February 8, 2016

https://doi.org/10.3892/ol.2016.4204
Expand metrics +

Abstract

The proteasome inhibitor bortezomib is indicated for use in the treatment of multiple myeloma (MM) patients. The most common side effects are neurological and gastrointestinal, while severe pulmonary complications are rarely described. The present study reports the case of a 62‑year‑old man with immunoglobulin (Ig)G‑type MM who was treated with bortezomib, thalidomide and dexamethasone. Subsequent to the administration of chemotherapy, the patient developed an acute respiratory distress syndrome. High‑resolution computed tomography of the chest showed bilateral diffuse alveolar infiltrations and multiple subpleural lesions. A diagnosis of bortezomib‑induced severe pulmonary complications was formed. Systemic corticosteroid therapy led to a rapid improvement in clinical conditions and radiological findings. In addition, the present study reviewed the characteristics, including medical history, clinical manifestations, treatment strategies and outcomes, of all 16 MM patients with bortezomib‑induced severe pulmonary complications reported previously in Pubmed. It was indicated that patients who were male, of IgG type, with a relapse status and a previous history of auto‑PBSCT had a higher possibility of developing bortezomib‑induced severe pulmonary complications. Additionally, a relatively low dose rather than a high dose of corticosteroids could obtain a better outcome.

View Figures

View References

1	Smith L, McCourt O, Henrich M, Paton B, Yong K, Wardle J and Fisher A: Multiple myeloma and physical activity: A scoping review. BMJ Open. 5:e0095762015. View Article : Google Scholar : PubMed/NCBI
2	Kyle RA and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
3	Gozzetti A, Candi V, Papini G and Bocchia M: Therapeutic advancements in multiple myeloma. Front Oncol. 4:2412014. View Article : Google Scholar : PubMed/NCBI
4	Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fulciniti M, Munshi NC and Martinez-Lopez J: Deep response in multiple myeloma: A critical review. Biomed Res Int. 2015:8320492015. View Article : Google Scholar : PubMed/NCBI
6	Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, et al: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 107:3492–3494. 2006. View Article : Google Scholar : PubMed/NCBI
7	Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, et al: Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 23:1528–1534. 2009. View Article : Google Scholar : PubMed/NCBI
8	Boyer JE, Batra RB, Ascensao JL and Schechter GP: Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood. 108:11132006. View Article : Google Scholar : PubMed/NCBI
9	Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, Lazzarino M and Corso A: Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 25:3380–3381. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dun XY, Yuan ZG, Fu WJ, Zhang CY and Hou J: Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematol Oncol. 28:49–52. 2010.PubMed/NCBI
11	Kang W, Kim JS, Cho SH, Kim SK, Chang J and Park MS: Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. Yonsei Med J. 51:448–450. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yamaguchi T, Sasaki M and Itoh K: Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma. Jpn J Clin Oncol. 42:637–639. 2012. View Article : Google Scholar : PubMed/NCBI
13	Vandeix E, Favard F, Pichon N, Delage-Corre M, Melloni B and Clavel M: Bortezomib-induced bronchiolitis obliterans organizing pneumonia. Case Rep Pulmonol. 2012:4301412012.PubMed/NCBI
14	Chew E, Filsher R and Wei A: Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma. 48:212–213. 2007. View Article : Google Scholar : PubMed/NCBI
15	Pitini V, Arrigo C, Altavilla G and Naro C: Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? Leuk Res. 31:1027–1028. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles